Viewing 49 links | Contacts | Verified

Cancer Research Publications Collapse this group and show less information

Combined Blockade of Dll4 and VEGF In Patient Derived Renal Cell Carcinoma Models

Expand this link and show more information

Miles et al, Roswell Park Cancer Center and Regeneron Pharmaceuticals From 2012

Presented at 2012 AACR (Abstract 2329)

Combined Angiogenesis Blockade by Targeting VEGF and Ang2

Lalani et al, Regeneron Pharmaceuticals and BC Cancer Agency From 2011

Published in Molecular Cancer Therapeutics (AACR-NCI-EORTC Poster Abstract A10 )

Angiopoietin-2 Antibody Phase 1 Trial In Progress

Papadopoulus et al, Regeneron Pharmaceuticals From 2011

Published in JCO Suppl. (ASCO Poster Abstract TPS159)

Chemotherapy Penetration in Tumors

Tredan et al, Univ. Toronto and Novacea Inc. From 2009

Published in Cancer Research

Phase 1 Trial of AQ4N in Patients with Advanced Cancers

Papadopoulos et al, Novacea Inc. From 2008

Published in Clinical Cancer Research

Hypoxia Targeting in Human Solid Tumors

Albertella et al, Novacea Inc. From 2008

Published in Clinical Cancer Research

Tumor Targeting Prodrugs

Lalani et al, Novacea Inc. From 2007

Published in Clinical Cancer Research

Prognostic Biomarkers in Prostate Cancer

Graff et al, OHSU and Novacea Inc. From 2007

Published in Journal of Clinical Oncology

Modulation of Cancer-Associated Thrombosis

Coll-Sangrona et al, Florida Institute of Translational Research and Novacea, Inc. From 2007

Published in Blood

Cancer Immunotherapy & VEGF Blockade

Li et al, Cell Genesys Inc. From 2006

Published in Clinical Cancer Research

Anti-VEGF Gene Therapy for Brain Tumors

Harding et al, Cell Genesys Inc. From 2006

Published in Molecular Therapy

Inhibition of Metastasis

Lin et al, Cell Genesys Inc. From 2005

Published in Cancer Research

Anti-angiogenic Gene Therapy for Cancer

Lalani et al, Cell Genesys Inc. From 2004

Published in Molecular Therapy

T-cell Based Immunotherapy for Cancer

McKinnon et al, Tom Baker Cancer Center and University of Calgary From 1993

Published in Surgery

Cure Hunter

CureHunter.com Discovery Engine From 2009

Virology & Inflammation Publications Collapse this group and show less information

Use of Chemokine Receptors by Poxviruses

Lalani et al, Univ. Alberta and Robarts Research Institute From 1999

Published in Science

Potential Link Between Smallpox and HIV?

Science Daily (Dec. 6, 1999)

Published in Science Daily

Cytokine and Chemokine Blockade for Vascular Injury

Liu et al, Robarts Research Institute and Univ. Western Ontario From 2000

Published in Journal of Clinical Investigation

Immune Evasion Strategies by Viruses

Lalani & McFadden, Howard Hughes Medical Institute and Univ. Western Ontario From 1999

Published in Immunology Today

Strategies of Chemokine Inhibition by Myxoma Virus

Lalani et al, Univ. Alberta and Robarts Research Institute From 1997

Published in Journal of Virology

Poxvirus Strategies to Subvert Chemokines & Inflammation

Lalani and McFadden, Univ. Alberta From 1997

Published in Journal of Leukocyte Biology

Viruses & Cytokines Book Chapter

Lalani et al, Oxford Press From 1999

Published in DNA Viruses: A Practical Approach (Oxford Press)

Doctoral Thesis

A.S. Lalani, University of Alberta From 1999

Published by The National Library of Canada

Patents

US Patent 7,186,699 (Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes)

Harding et al From 2007

PCT/US2008/003630 (Prevention and treatment of infectious conditions with active vitamin D compounds or mimics thereof )

Lalani et al From 2008

US Patent 20070117784 (Treatment of hyperproliferative diseases with anthraquinones)

Cleland et al From 2007

PCT WO/2007/098091 (Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs)

Curd et al From 2007

PCT WO/2008/103320 (Methods of treating ophthalmic disorders with anthraquinones)

Curd et al From 2008

PCT WO/2008/005560 (Prevention of thrombotic disorders with active vitamin D compounds)

Goodwin et al From 2008

US Patent Application 20100016252 (Mannich Base N-Oxide Drugs)

Keana et al From 2010

PCT WO/2007/095389 (Treatment of hyperproliferative diseases with camptothecine N-oxide and analogs)

Curd et al From 2007

PCT/US2007/004251 (Treatment of hyperproliferative diseases with N-oxides of estrogen receptor modulators)

Curd et al From 2007

PCT/US2007/004250 (Treatment of hyperproliferative diseases with methotrexate N-oxide and analogs)

Curd et al From 2007

PCT/US2007/023698 (Nitric oxide synthase as a marker for treatment with bioreducible prodrugs)

Curd et al From 2008

Misc. Press Collapse this group and show less information

Clinical Trial Acronyms at ASCO 2012 - Scrabble Edition

Published in Pharma Strategy Blog (May 13, 2012)

Combined Anti-Angiogenesis Blockade as a Cancer Treatment Strategy

Published in ScienceDaily (Nov 13th, 2011)

Clinical Trial Acronymania

Published in Pharma Strategy Blog (June 1, 2011)

Proof-of-Principle Clinical Study in Human Solid Tumors

Published by Rueters (Feb. 15, 2008)

Prostate Cancer Link Offers Hope

Published in the Calgary Herald (Feb. 23rd, 2007)

Prostate Cancer Trial

Published in the Calgary Herald (Feb. 23rd, 2007)

University of Calgary Alumni Profile

Published in U Magazine (Spring, 2007)

Life Science Entrepeneurs' Forum

Hosted by Fountain Blue (Aug. 2007)

Big Discovery in AIDS Research

Published by CBC News (Dec. 2nd, 1999)

'Playing in the sandbox' yields major AIDS breakthrough?

Published in EurekAlert! (Dec. 20th, 1999)

HIV & Poxviruses Use Same Receptor

Published in Applied Genetic News (Dec. 19th, 1999)

Past CJSW-FM Radio DJ's: Where Are They Now?

Published in FFWD Weekly (Jan. 6th 2005)

Editorial Board Memberships Collapse this group and show less information

Editorial Board: Journal of Translational Medicine

BioMed Central Open Access Journal

Editorial Board: Clinical Medicine: Oncology

Libertas Academica Open Access Journal

Editorial Board: Current Angiogenesis

Bentham Science Publishers

Alshad Lalani

New York, NY

Alshad S. Lalani Ph.D., specializes in translational cancer medicine and early clinical development for targeted anticancer agents in the biotechnology industry. He currently serves as Director, Strategic Oncology Development at a New York-based biopharmaceutical firm.

Alshad Lalani

Al Lalani

Alshad S. Lalani Ph.D., specializes in translational cancer medicine and early clinical development for targeted anticancer agents in the biotechnology industry. He currently serves as Director, Strategic Oncology Development at a New York-based biopharmaceutical firm.

ClaimID is a simple way to manage your online identity. This is the claimID page of Alshad Lalani.

Verified OpenID Identities

Verified Claimed Links (0/49)

Contacts

Alshad Lalani

Alshad Lalani +